These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9484873

  • 21. [Grepafloxacin (Raxar)].
    Friis HM.
    Ugeskr Laeger; 1998 Jul 20; 160(30):4438-41. PubMed ID: 9691842
    [No Abstract] [Full Text] [Related]

  • 22. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan 30; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of grepafloxacin.
    Efthymiopoulos C.
    J Antimicrob Chemother; 1997 Dec 30; 40 Suppl A():35-43. PubMed ID: 9484872
    [Abstract] [Full Text] [Related]

  • 24. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec 30; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 25. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C, Bramer SL, Maroli A, Gambertoglio JG.
    Clin Pharmacokinet; 1997 Dec 30; 33 Suppl 1():32-8. PubMed ID: 9433654
    [Abstract] [Full Text] [Related]

  • 26. Effect of age and gender on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C, Bramer SL, Maroli A.
    Clin Pharmacokinet; 1997 Dec 30; 33 Suppl 1():9-17. PubMed ID: 9433651
    [Abstract] [Full Text] [Related]

  • 27. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
    Norrby SR.
    J Antimicrob Chemother; 1997 Dec 30; 40 Suppl A():99-101. PubMed ID: 9484879
    [No Abstract] [Full Text] [Related]

  • 28. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
    Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ.
    Antimicrob Agents Chemother; 1993 May 30; 37(5):1073-81. PubMed ID: 8517694
    [Abstract] [Full Text] [Related]

  • 29. Lomefloxacin versus amoxicillin in the treatment of acute exacerbations of chronic bronchitis: an Italian multicenter study.
    Grassi C, Albera C, Pozzi E.
    Am J Med; 1992 Apr 06; 92(4A):103S-107S. PubMed ID: 1316058
    [Abstract] [Full Text] [Related]

  • 30. [The importance of fluoroquinolones in treating pneumonia in the elderly].
    Belousov IuB, Efremenkova OV, Sokolov AV, Tishenkova IF.
    Antibiot Khimioter; 1999 Apr 06; 44(12):23-6. PubMed ID: 10687030
    [No Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis.
    Gotfried MH, Ellison WT.
    Am J Med; 1992 Apr 06; 92(4A):108S-113S. PubMed ID: 1316059
    [Abstract] [Full Text] [Related]

  • 32. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
    Efthymiopoulos C, Bramer SL, Maroli A, Flaherty JF, Wolfe E, Bass N, Somberg K.
    Clin Pharmacokinet; 1997 Apr 06; 33 Suppl 1():25-31. PubMed ID: 9433653
    [Abstract] [Full Text] [Related]

  • 33. [Efficacy of lomefloxacin in treatment of patients with chronic bronchitis].
    Fedoseev GB, Emel'ianov AV, Rudinskiĭ KA, Shevelev SE, Bykova AV.
    Antibiot Khimioter; 1998 Apr 06; 43(10):24-6. PubMed ID: 9825106
    [Abstract] [Full Text] [Related]

  • 34. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H, Vogel F, Elies W.
    Clin Ther; 1999 Jan 06; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of marbofloxacin in horses.
    Bousquet-Melou A, Bernard S, Schneider M, Toutain PL.
    Equine Vet J; 2002 Jul 06; 34(4):366-72. PubMed ID: 12117108
    [Abstract] [Full Text] [Related]

  • 36. Rufloxacin once daily in acute exacerbations of chronic bronchitis.
    Dirksen M, Focht J, Boerema J.
    Infection; 1991 Jul 06; 19(4):297-300. PubMed ID: 1917050
    [Abstract] [Full Text] [Related]

  • 37. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D.
    J Antimicrob Chemother; 1997 Dec 06; 40 Suppl A():31-4. PubMed ID: 9484871
    [Abstract] [Full Text] [Related]

  • 38. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ.
    J Chemother; 1999 Dec 06; 11(6):426-39. PubMed ID: 10678784
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
    Topkis S, Swarz H, Breisch SA, Maroli AN.
    Clin Ther; 1997 Dec 06; 19(5):975-88. PubMed ID: 9385485
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
    Chodosh S, Schreurs A, Siami G, Barkman HW, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S.
    Clin Infect Dis; 1998 Oct 06; 27(4):730-8. PubMed ID: 9798025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.